Pivotal study to assess the efficacy, safety and tolerability of dupilumab in patients with moderate-to- severe COPD with Type 2 inflammation (BOREAS)
University of North Carolina at Chapel Hill
40 - 80 years
Patients who have been diagnosed with moderate to severe COPD and have been on inhalers. Eligible participants should be between the ages of 40 to 80, and on daily inhalers, and have had at least one breathing flare in the past year.